Review



blocking peptides for vglut1 135-3p  (Synaptic Systems)


Bioz Verified Symbol Synaptic Systems is a verified supplier
Bioz Manufacturer Symbol Synaptic Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Synaptic Systems blocking peptides for vglut1 135-3p
    Blocking Peptides For Vglut1 135 3p, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blocking peptides for vglut1 135-3p/product/Synaptic Systems
    Average 90 stars, based on 1 article reviews
    blocking peptides for vglut1 135-3p - by Bioz Stars, 2026-05
    90/100 stars

    Images



    Similar Products

    vglut1  (Alomone Labs)
    90
    Alomone Labs vglut1
    Long-lasting LPS treatment increases the expression of L-type Ca2+ channels at glutamatergic synapses. A, Top, Representative images of neurites of hippocampal neurons exposed to either vehicle or LPS for 48 h and double-immunostained with Cav1.2 antibodies (green) and the excitatory presynaptic marker <t>vGLUT1</t> (red). Merge panels represent synaptic puncta in which Cav1.2 and vGLUT1 colocalize (yellow; arrows). Bottom, Representative immunoreactivity intensity profiles of the colocalization experiments showing the increased occurrence of overlap between Cav1.2- and vGLUT1-positive puncta in the samples chronically treated with LPS. B, Quantification of the density of vGLUT1-positive puncta counted on 30 μm dendrite tracts starting from the neuronal body. Data are mean ± SEM from three independent experiments, each conducted in duplicate (veh = 30; LPS = 29). C, Quantification of the absolute Cav1.2/vGLUT1 colocalization area (top) and of the Cav1.2/vGLUT1 colocalization expressed in percent of the total Cav1.2-immunopositive area (bottom) in vehicle- and LPS-treated neurons (veh = 66; LPS = 97). Data are mean ± SEM. **p < 0.01 (unpaired Student's t test/Mann–Whitney U test).
    Vglut1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vglut1/product/Alomone Labs
    Average 90 stars, based on 1 article reviews
    vglut1 - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    blocking peptides for vglut1 135-3p  (Synaptic Systems)
    90
    Synaptic Systems blocking peptides for vglut1 135-3p
    Long-lasting LPS treatment increases the expression of L-type Ca2+ channels at glutamatergic synapses. A, Top, Representative images of neurites of hippocampal neurons exposed to either vehicle or LPS for 48 h and double-immunostained with Cav1.2 antibodies (green) and the excitatory presynaptic marker <t>vGLUT1</t> (red). Merge panels represent synaptic puncta in which Cav1.2 and vGLUT1 colocalize (yellow; arrows). Bottom, Representative immunoreactivity intensity profiles of the colocalization experiments showing the increased occurrence of overlap between Cav1.2- and vGLUT1-positive puncta in the samples chronically treated with LPS. B, Quantification of the density of vGLUT1-positive puncta counted on 30 μm dendrite tracts starting from the neuronal body. Data are mean ± SEM from three independent experiments, each conducted in duplicate (veh = 30; LPS = 29). C, Quantification of the absolute Cav1.2/vGLUT1 colocalization area (top) and of the Cav1.2/vGLUT1 colocalization expressed in percent of the total Cav1.2-immunopositive area (bottom) in vehicle- and LPS-treated neurons (veh = 66; LPS = 97). Data are mean ± SEM. **p < 0.01 (unpaired Student's t test/Mann–Whitney U test).
    Blocking Peptides For Vglut1 135 3p, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blocking peptides for vglut1 135-3p/product/Synaptic Systems
    Average 90 stars, based on 1 article reviews
    blocking peptides for vglut1 135-3p - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    blocking peptides vglut1 cat. no. 135-30p  (Synaptic Systems)
    90
    Synaptic Systems blocking peptides vglut1 cat. no. 135-30p
    Long-lasting LPS treatment increases the expression of L-type Ca2+ channels at glutamatergic synapses. A, Top, Representative images of neurites of hippocampal neurons exposed to either vehicle or LPS for 48 h and double-immunostained with Cav1.2 antibodies (green) and the excitatory presynaptic marker <t>vGLUT1</t> (red). Merge panels represent synaptic puncta in which Cav1.2 and vGLUT1 colocalize (yellow; arrows). Bottom, Representative immunoreactivity intensity profiles of the colocalization experiments showing the increased occurrence of overlap between Cav1.2- and vGLUT1-positive puncta in the samples chronically treated with LPS. B, Quantification of the density of vGLUT1-positive puncta counted on 30 μm dendrite tracts starting from the neuronal body. Data are mean ± SEM from three independent experiments, each conducted in duplicate (veh = 30; LPS = 29). C, Quantification of the absolute Cav1.2/vGLUT1 colocalization area (top) and of the Cav1.2/vGLUT1 colocalization expressed in percent of the total Cav1.2-immunopositive area (bottom) in vehicle- and LPS-treated neurons (veh = 66; LPS = 97). Data are mean ± SEM. **p < 0.01 (unpaired Student's t test/Mann–Whitney U test).
    Blocking Peptides Vglut1 Cat. No. 135 30p, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blocking peptides vglut1 cat. no. 135-30p/product/Synaptic Systems
    Average 90 stars, based on 1 article reviews
    blocking peptides vglut1 cat. no. 135-30p - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    blocking peptides for vglut1 cat. no. 135-3p  (Synaptic Systems)
    90
    Synaptic Systems blocking peptides for vglut1 cat. no. 135-3p
    Long-lasting LPS treatment increases the expression of L-type Ca2+ channels at glutamatergic synapses. A, Top, Representative images of neurites of hippocampal neurons exposed to either vehicle or LPS for 48 h and double-immunostained with Cav1.2 antibodies (green) and the excitatory presynaptic marker <t>vGLUT1</t> (red). Merge panels represent synaptic puncta in which Cav1.2 and vGLUT1 colocalize (yellow; arrows). Bottom, Representative immunoreactivity intensity profiles of the colocalization experiments showing the increased occurrence of overlap between Cav1.2- and vGLUT1-positive puncta in the samples chronically treated with LPS. B, Quantification of the density of vGLUT1-positive puncta counted on 30 μm dendrite tracts starting from the neuronal body. Data are mean ± SEM from three independent experiments, each conducted in duplicate (veh = 30; LPS = 29). C, Quantification of the absolute Cav1.2/vGLUT1 colocalization area (top) and of the Cav1.2/vGLUT1 colocalization expressed in percent of the total Cav1.2-immunopositive area (bottom) in vehicle- and LPS-treated neurons (veh = 66; LPS = 97). Data are mean ± SEM. **p < 0.01 (unpaired Student's t test/Mann–Whitney U test).
    Blocking Peptides For Vglut1 Cat. No. 135 3p, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blocking peptides for vglut1 cat. no. 135-3p/product/Synaptic Systems
    Average 90 stars, based on 1 article reviews
    blocking peptides for vglut1 cat. no. 135-3p - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    blocking peptides for vglut1  (Synaptic Systems)
    90
    Synaptic Systems blocking peptides for vglut1
    <t>VGLUT1-</t> and VGLUT2- immunopositive axons costained for PGP9.5 (arrowheads) indicating VGLUT1 and VGLUT2 were expressed in pulpal axons. Scale bar = 20 µm.
    Blocking Peptides For Vglut1, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blocking peptides for vglut1/product/Synaptic Systems
    Average 90 stars, based on 1 article reviews
    blocking peptides for vglut1 - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    blocking peptides for vglut1 #135-3p  (Synaptic Systems)
    90
    Synaptic Systems blocking peptides for vglut1 #135-3p
    <t>VGLUT1-</t> and VGLUT2- immunopositive axons costained for PGP9.5 (arrowheads) indicating VGLUT1 and VGLUT2 were expressed in pulpal axons. Scale bar = 20 µm.
    Blocking Peptides For Vglut1 #135 3p, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blocking peptides for vglut1 #135-3p/product/Synaptic Systems
    Average 90 stars, based on 1 article reviews
    blocking peptides for vglut1 #135-3p - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    vglut1 blocking peptide  (Synaptic Systems)
    90
    Synaptic Systems vglut1 blocking peptide
    <t>VGLUT1-</t> and VGLUT2- immunopositive axons costained for PGP9.5 (arrowheads) indicating VGLUT1 and VGLUT2 were expressed in pulpal axons. Scale bar = 20 µm.
    Vglut1 Blocking Peptide, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vglut1 blocking peptide/product/Synaptic Systems
    Average 90 stars, based on 1 article reviews
    vglut1 blocking peptide - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Long-lasting LPS treatment increases the expression of L-type Ca2+ channels at glutamatergic synapses. A, Top, Representative images of neurites of hippocampal neurons exposed to either vehicle or LPS for 48 h and double-immunostained with Cav1.2 antibodies (green) and the excitatory presynaptic marker vGLUT1 (red). Merge panels represent synaptic puncta in which Cav1.2 and vGLUT1 colocalize (yellow; arrows). Bottom, Representative immunoreactivity intensity profiles of the colocalization experiments showing the increased occurrence of overlap between Cav1.2- and vGLUT1-positive puncta in the samples chronically treated with LPS. B, Quantification of the density of vGLUT1-positive puncta counted on 30 μm dendrite tracts starting from the neuronal body. Data are mean ± SEM from three independent experiments, each conducted in duplicate (veh = 30; LPS = 29). C, Quantification of the absolute Cav1.2/vGLUT1 colocalization area (top) and of the Cav1.2/vGLUT1 colocalization expressed in percent of the total Cav1.2-immunopositive area (bottom) in vehicle- and LPS-treated neurons (veh = 66; LPS = 97). Data are mean ± SEM. **p < 0.01 (unpaired Student's t test/Mann–Whitney U test).

    Journal: The Journal of Neuroscience

    Article Title: Presynaptic L-Type Ca 2+ Channels Increase Glutamate Release Probability and Excitatory Strength in the Hippocampus during Chronic Neuroinflammation

    doi: 10.1523/JNEUROSCI.2981-19.2020

    Figure Lengend Snippet: Long-lasting LPS treatment increases the expression of L-type Ca2+ channels at glutamatergic synapses. A, Top, Representative images of neurites of hippocampal neurons exposed to either vehicle or LPS for 48 h and double-immunostained with Cav1.2 antibodies (green) and the excitatory presynaptic marker vGLUT1 (red). Merge panels represent synaptic puncta in which Cav1.2 and vGLUT1 colocalize (yellow; arrows). Bottom, Representative immunoreactivity intensity profiles of the colocalization experiments showing the increased occurrence of overlap between Cav1.2- and vGLUT1-positive puncta in the samples chronically treated with LPS. B, Quantification of the density of vGLUT1-positive puncta counted on 30 μm dendrite tracts starting from the neuronal body. Data are mean ± SEM from three independent experiments, each conducted in duplicate (veh = 30; LPS = 29). C, Quantification of the absolute Cav1.2/vGLUT1 colocalization area (top) and of the Cav1.2/vGLUT1 colocalization expressed in percent of the total Cav1.2-immunopositive area (bottom) in vehicle- and LPS-treated neurons (veh = 66; LPS = 97). Data are mean ± SEM. **p < 0.01 (unpaired Student's t test/Mann–Whitney U test).

    Article Snippet: The presynaptic localization of the L-type Ca 2+ channel was analyzed in treated neurons by evaluating the immunoreactivity of L-type Ca 2+ channel (1:200, Alomone Labs) ( Hermosilla et al., 2017 ) in vGLUT1-positive excitatory boutons.

    Techniques: Expressing, Marker, MANN-WHITNEY

    VGLUT1- and VGLUT2- immunopositive axons costained for PGP9.5 (arrowheads) indicating VGLUT1 and VGLUT2 were expressed in pulpal axons. Scale bar = 20 µm.

    Journal: PLoS ONE

    Article Title: Expression of Vesicular Glutamate Transporters VGLUT1 and VGLUT2 in the Rat Dental Pulp and Trigeminal Ganglion following Inflammation

    doi: 10.1371/journal.pone.0109723

    Figure Lengend Snippet: VGLUT1- and VGLUT2- immunopositive axons costained for PGP9.5 (arrowheads) indicating VGLUT1 and VGLUT2 were expressed in pulpal axons. Scale bar = 20 µm.

    Article Snippet: Preadsorption controls with blocking peptides for VGLUT1 (15 μg/ml; #135-3P, Synaptic Systems) and VGLUT2 (10 μg/ml; #G07B-VGLUT2-AG, Frontier Science) also completely abolished the respective staining.

    Techniques:

    Expression of VGLUT1 in pulpal axons in control (A) and CFA 1-day (B) and CFA 3-day (C) groups. VGLUT1 is expressed in many axons in the peripheral portion of the coronal pulp. D–I: Expression of VGLUT2 in pulpal axons in control (D, E), CFA 1-day (F), and CFA 3-day (G–I) groups. In the control group, VGLUT2 is expressed in a small number of axons in the peripheral portion of coronal pulp (D) and few axons in the radicular pulp (E). However, it is expressed in a large number of axons in the peripheral portion (F, G), the core of the coronal pulp (H), and in radicular pulp (I) in the CFA 1-day and CFA 3-day groups. Scale bar = 20 µm.

    Journal: PLoS ONE

    Article Title: Expression of Vesicular Glutamate Transporters VGLUT1 and VGLUT2 in the Rat Dental Pulp and Trigeminal Ganglion following Inflammation

    doi: 10.1371/journal.pone.0109723

    Figure Lengend Snippet: Expression of VGLUT1 in pulpal axons in control (A) and CFA 1-day (B) and CFA 3-day (C) groups. VGLUT1 is expressed in many axons in the peripheral portion of the coronal pulp. D–I: Expression of VGLUT2 in pulpal axons in control (D, E), CFA 1-day (F), and CFA 3-day (G–I) groups. In the control group, VGLUT2 is expressed in a small number of axons in the peripheral portion of coronal pulp (D) and few axons in the radicular pulp (E). However, it is expressed in a large number of axons in the peripheral portion (F, G), the core of the coronal pulp (H), and in radicular pulp (I) in the CFA 1-day and CFA 3-day groups. Scale bar = 20 µm.

    Article Snippet: Preadsorption controls with blocking peptides for VGLUT1 (15 μg/ml; #135-3P, Synaptic Systems) and VGLUT2 (10 μg/ml; #G07B-VGLUT2-AG, Frontier Science) also completely abolished the respective staining.

    Techniques: Expressing, Control

    VGLUT1 and VGLUT2 are expressed in many CD64+ cells (arrowhead) as well as in axons (arrow) in the inflamed dental pulp. Scale bar = 20 µm.

    Journal: PLoS ONE

    Article Title: Expression of Vesicular Glutamate Transporters VGLUT1 and VGLUT2 in the Rat Dental Pulp and Trigeminal Ganglion following Inflammation

    doi: 10.1371/journal.pone.0109723

    Figure Lengend Snippet: VGLUT1 and VGLUT2 are expressed in many CD64+ cells (arrowhead) as well as in axons (arrow) in the inflamed dental pulp. Scale bar = 20 µm.

    Article Snippet: Preadsorption controls with blocking peptides for VGLUT1 (15 μg/ml; #135-3P, Synaptic Systems) and VGLUT2 (10 μg/ml; #G07B-VGLUT2-AG, Frontier Science) also completely abolished the respective staining.

    Techniques:

    A : The density (area fraction) of VGLUT1+ pulpal axons is not significantly different between CFA 1-day or CFA 3-day groups and control, whereas the density of VGLUT2+ axons is significantly higher in the CFA 1-day, CFA 3-day groups than control. N = 3 animals in each group. *p<0.01. B : Representative images of the Western blot assay. C : Quantitative analysis of VGLUT1 and VGLUT2 protein in the dental pulp. Protein levels of VGLUT1 and VGLUT2 in the pulp are significantly higher in the CFA 1-day, CFA 3-day groups than control. This difference is bigger for VGLUT2 (3.9 and 4.3 fold higher in the CFA 1-day and CFA 3-day groups than control) than for VGLUT1 (2.9 and 3.1 fold higher in the CFA 1-day and CFA 3-day groups than control). N = 5 animals in each group. *p<0.01.

    Journal: PLoS ONE

    Article Title: Expression of Vesicular Glutamate Transporters VGLUT1 and VGLUT2 in the Rat Dental Pulp and Trigeminal Ganglion following Inflammation

    doi: 10.1371/journal.pone.0109723

    Figure Lengend Snippet: A : The density (area fraction) of VGLUT1+ pulpal axons is not significantly different between CFA 1-day or CFA 3-day groups and control, whereas the density of VGLUT2+ axons is significantly higher in the CFA 1-day, CFA 3-day groups than control. N = 3 animals in each group. *p<0.01. B : Representative images of the Western blot assay. C : Quantitative analysis of VGLUT1 and VGLUT2 protein in the dental pulp. Protein levels of VGLUT1 and VGLUT2 in the pulp are significantly higher in the CFA 1-day, CFA 3-day groups than control. This difference is bigger for VGLUT2 (3.9 and 4.3 fold higher in the CFA 1-day and CFA 3-day groups than control) than for VGLUT1 (2.9 and 3.1 fold higher in the CFA 1-day and CFA 3-day groups than control). N = 5 animals in each group. *p<0.01.

    Article Snippet: Preadsorption controls with blocking peptides for VGLUT1 (15 μg/ml; #135-3P, Synaptic Systems) and VGLUT2 (10 μg/ml; #G07B-VGLUT2-AG, Frontier Science) also completely abolished the respective staining.

    Techniques: Control, Western Blot

    A: Immunofluorescent staining for VGLUT1 (a, b) and VGLUT2 (c, d) in the rat trigeminal ganglion in the control (a, c) and CFA 1-day (b, d) groups. VGLUT1 is expressed predominantly in medium- and large-sized somata (a, b), whereas VGLUT2 is expressed predominantly in small- and medium-sized somata (c, d). The number of VGLUT1+ somata of all somata is not different between control (a) and CFA 1-day group (b), whereas that of VGLUT2+ soma is significantly higher in the CFA 1-day (d) than in the control (c) groups. Scale bar = 50 µm. B: The density of VGLUT2+ somata (fraction of all somata) is significantly higher for the CFA 1-day, CFA 3-day groups than control, whereas the density of VGLUT1+ soma is not significantly different between CFA 1-day or CFA 3-day groups and control. N = 3 animals in each group. *p<0.01. C: Representative images of the Western blot assay for VGLUT1 and VGLUT2 in the rat trigeminal ganglion. D: Quantitative analysis of VGLUT1 and VGLUT2 protein in the trigeminal ganglion. The VGLUT2 protein levels are significantly higher in the CFA 1-day and CFA 3-day groups than for the control, whereas the VGLUT1 protein levels are not different between CFA 1-day or CFA 3-day groups and the control group. N = 5 animals in each group. *p<0.01.

    Journal: PLoS ONE

    Article Title: Expression of Vesicular Glutamate Transporters VGLUT1 and VGLUT2 in the Rat Dental Pulp and Trigeminal Ganglion following Inflammation

    doi: 10.1371/journal.pone.0109723

    Figure Lengend Snippet: A: Immunofluorescent staining for VGLUT1 (a, b) and VGLUT2 (c, d) in the rat trigeminal ganglion in the control (a, c) and CFA 1-day (b, d) groups. VGLUT1 is expressed predominantly in medium- and large-sized somata (a, b), whereas VGLUT2 is expressed predominantly in small- and medium-sized somata (c, d). The number of VGLUT1+ somata of all somata is not different between control (a) and CFA 1-day group (b), whereas that of VGLUT2+ soma is significantly higher in the CFA 1-day (d) than in the control (c) groups. Scale bar = 50 µm. B: The density of VGLUT2+ somata (fraction of all somata) is significantly higher for the CFA 1-day, CFA 3-day groups than control, whereas the density of VGLUT1+ soma is not significantly different between CFA 1-day or CFA 3-day groups and control. N = 3 animals in each group. *p<0.01. C: Representative images of the Western blot assay for VGLUT1 and VGLUT2 in the rat trigeminal ganglion. D: Quantitative analysis of VGLUT1 and VGLUT2 protein in the trigeminal ganglion. The VGLUT2 protein levels are significantly higher in the CFA 1-day and CFA 3-day groups than for the control, whereas the VGLUT1 protein levels are not different between CFA 1-day or CFA 3-day groups and the control group. N = 5 animals in each group. *p<0.01.

    Article Snippet: Preadsorption controls with blocking peptides for VGLUT1 (15 μg/ml; #135-3P, Synaptic Systems) and VGLUT2 (10 μg/ml; #G07B-VGLUT2-AG, Frontier Science) also completely abolished the respective staining.

    Techniques: Staining, Control, Western Blot